NMLSF (Restart Life Sciences) Risk Assessment

View and export this data going back to 2013. Start your Free Trial

What is Restart Life Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Restart Life Sciences is: No Data: Cannot be evaluated.

Competitive Comparison of Restart Life Sciences's Risk Assessment

For the Biotechnology subindustry, Restart Life Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Restart Life Sciences's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Risk Assessment falls into.

Restart Life Sciences (OTCPK:NMLSF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Restart Life Sciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Restart Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (OTCPK:NMLSF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

HN3:Germany HN3:Germany HEAL.X:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. It is focus is on creating health foods that address the needs of this community. Its Flagship developments includes Autism Spectrum, Health-Related Foods, Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA).

Restart Life Sciences Headlines

From GuruFocus

BioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glaucoma, and Autism

By GuruFocusNews GuruFocusNews • 05-13-2022

By GuruFocusNews GuruFocusNews • 05-23-2022

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

By PRNewswire PRNewswire • 10-26-2021

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

By PRNewswire PRNewswire • 11-09-2021

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

By PRNewswire PRNewswire • 02-16-2022

By GuruFocusNews GuruFocusNews • 06-22-2022

By GuruFocusNews GuruFocusNews • 06-02-2022

Healthcare Breakthroughs: NVAX, MITO, LMLLF, NMLSF; Life Sciences Leaders Report Latest Advances in Vaccines, Novel Therapeutics for Autism, Neurodegenerative, Oncology, and Glaucoma

By GuruFocusNews GuruFocusNews • 06-28-2022

Nova Mentis Begins Enrollment in North American Autism Study

By PRNewswire PRNewswire • 03-23-2022

By PurpleRose PurpleRose • 07-12-2022